Skip to main content
. 2010 Mar-Apr;2(2):165–175. doi: 10.4161/mabs.2.2.11360

Figure 1.

Figure 1

Blockade of the VEGF pathway with mAbs. The specificity of the VEGF family ligands for the VEGF receptors and coreceptors are shown. The clinically-relevant mAbs targeting the anti-VEGF pathway discussed in this review are placed based on their blockade of VEGF ligand or receptor. The ligand-binding antibodies bevacizumab (bev), r84, and VEGF-Trap inhibit ligand binding to the indicated receptor. IMC-18F1 and IMC-1121B bind VEGFR1 and VEGFR2 respectively, and prevent ligand binding.